Abstract:Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy with dismal prognosis. Identification of better biomarkers remained a priority to improve established stratification and guide therapeutic decisions. Therefore, we extracted the RNA sequence data and clinical characteristics of AML from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression database (GTEx) to identify the key factors for prognosis. We found UNC93B1 was highly expressed in AML patients and significantly linked to poor clinical features (p < 0.05). We further validated the high expression of UNC93B1 in another independent AML cohort from GEO datasets (p < 0.001) and performed quantitative PCR of patient samples to confirm the overexpression of UNC93B1 in AML (p < 0.005). Moreover, we discovered high level of UNC93B1 was an independent prognostic factor for poorer outcome both in univariate analysis and multivariate regression (p < 0.001). Then we built a nomogram model based on UNC93B1 expression, age, FAB subtype and cytogenetic risk, the concordance index of which for predicting overall survival was 0.729 (p < 0.001). Time-dependent ROC analysis for predicting survival outcome at different time points by UNC93B1 showed the cumulative 2-year survival rate was 43.7%, and 5-year survival rate was 21.9%. The differentially expressed genes (DEGs) between two groups divided by UNC93B1 expression level were enriched in innate immune signaling and metabolic process pathway. Protein–protein interaction (PPI) network indicated four hub genes (S100A9, CCR1, MRC1 and CD1C) interacted with UNC93B1, three of which were also significantly linked to inferior outcome. Furthermore, we discovered high UNC93B1 tended to be infiltrated by innate immune cells, including Macrophages, Dendritic cells, Neutrophils, Eosinophils, and NK CD56dim cells. We also found UNC93B1 had a significantly positive correlation with CD14, CD68 and almost all Toll-like receptors. Finally, we revealed negatively correlated expression of UNC93B1 and BCL2 in AML and conjectured that high-UNC93B1 monocytic AML is more resistant to venetoclax. And we found high MCL-1 expression compensated for BCL-2 loss, thus, we proposed MCL-1 inhibitor might overcome the resistance of venetoclax in AML. Altogether, our findings demonstrated the utility of UNC93B1 as a powerful poor prognostic predictor and alternative therapeutic target.

High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia

FLT3-ITD As a Prognostic Factor for Chinese Patients with Acute Myeloid Leukemia

Prognostic Significance of Huntingtin Interacting Protein 1 Expression on Patients with Acute Myeloid Leukemia

The diagnostic/prognostic roles and biological function of the IFIT family members in acute myeloid leukemia

High IDH1 Expression is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia.

Expression and Clinical Significance of ID1 Gene in Acute Myeloid Leukemia

High Expression of Mir-363 Predicts Poor Prognosis and Guides Treatment Selection in Acute Myeloid Leukemia

FLT3LG and IFITM3P6 Consolidate T Cell Activity in the Bone Marrow Microenvironment and Are Prognostic Factors in Acute Myelocytic Leukemia

Expression of the Interferon Regulatory Factor Family and Its Prognostic Value in Acute Myeloid Leukemia

The Clinical Significance of Fms-Like Tyrosine Kinase3 Expression for Evaluating the Prognosis of Acute Myeloid Leukemia

High Expression of RhoBTB3 Predicts Favorable Chemothrapy Outcomes in non-M3 Acute Myeloid Leukemia

FLT3 Gene Expression and Its Clinical Significance in Acute Myeloid Leukemia

High Expression Levels of ACTN1 and ACTN3 Indicate Unfavorable Prognosis in Acute Myeloid Leukemia.

The Clinical and Prognostic Significance of Acute Myeloid Leukemia with FLT3-ITD

A Novel Immune Prognostic Model of Non-M3 Acute Myeloid Leukemia.

IER3 (IEX‐1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients

Identification and validation of inferior prognostic genes associated with immune signatures and chemotherapy outcome in acute myeloid leukemia

Tim-3 As A Leukemia Stem Cell Specific Marker Expressing On Bone Marrow Mononuclear Cells Is A Factor For Prognosis Evaluation In Patients With Acute Myelogenous Leukemia

High-expression of the Innate-Immune Related Gene UNC93B1 Predicts Inferior Outcomes in Acute Myeloid Leukemia

Expression of interferon regulatory factor family and its prognostic value in acute myeloid leukemia

High expression level of the FTH1 gene is associated with poor prognosis in children with non-M3 acute myeloid leukemia